dc.contributor.author | Athauda, A | |
dc.contributor.author | Watkins, D | |
dc.contributor.author | Mohammed, K | |
dc.contributor.author | Chau, I | |
dc.contributor.author | Starling, N | |
dc.contributor.author | Rao, S | |
dc.contributor.author | Tait, D | |
dc.contributor.author | Aitken, K | |
dc.contributor.author | Cunningham, D | |
dc.date.accessioned | 2018-11-14T12:15:16Z | |
dc.date.issued | 2018-10 | |
dc.identifier.citation | Anticancer research, 2018, 38 (10), pp. 5943 - 5949 | |
dc.identifier.issn | 0250-7005 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2936 | |
dc.identifier.eissn | 1791-7530 | |
dc.identifier.doi | 10.21873/anticanres.12940 | |
dc.description.abstract | Background/aim Cisplatin-based radical chemoradiotherapy (CRT) is utilised in oesophagogastric (OG) cancer but the toxicity profile of cisplatin limits its use. This study aimed to evaluate the clinical characteristics and outcomes of patients treated with either cisplatin or carboplatin based CRT at our institution.Materials and methods This is a retrospective analysis of patients with localised OG cancer undergoing CRT with cisplatin/fluoropyrimidine (CX/F) or carboplatin/fluoropyrimidine (CarboX/F) between January 2001 and December 2014.Results A total of 91 eligible patients were included. Median age was 65 years (IQR=57-75) for CX/F and 77 years (IQR=69-80) for CarboX/F. Adenocarcinoma histology and Charlson comorbidity index were higher in the CarboX/F group. Endoscopic complete response (CR) was achieved in 64% of CX/F group and 48% of CarboX/F group (p=0.19). The median PFS for CX/F was 31.0 months (95%CI=18.2-NE) vs. 18.7 months for CarboX/F (95%CI=13.5-30.4; HR=1.49, p=0.21).Conclusion Despite significant differences in baseline clinical characteristics, patients treated with carboplatin CRT demonstrated no significant difference in PFS or endoscopic CR rate, compared to those treated with cisplatin. | |
dc.format | Print | |
dc.format.extent | 5943 - 5949 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Esophagogastric Junction | |
dc.subject | Humans | |
dc.subject | Adenocarcinoma | |
dc.subject | Carcinoma, Squamous Cell | |
dc.subject | Esophageal Neoplasms | |
dc.subject | Stomach Neoplasms | |
dc.subject | Cisplatin | |
dc.subject | Paclitaxel | |
dc.subject | Carboplatin | |
dc.subject | Fluorouracil | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Prognosis | |
dc.subject | Survival Rate | |
dc.subject | Retrospective Studies | |
dc.subject | Follow-Up Studies | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Chemoradiotherapy | |
dc.subject | Tertiary Care Centers | |
dc.title | Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-09-04 | |
rioxxterms.versionofrecord | 10.21873/anticanres.12940 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-10 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Anticancer research | |
pubs.issue | 10 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 38 | en_US |
pubs.embargo.terms | Not known | |
icr.researchteam | Gastrointestinal Cancers Clinical Trials | en_US |
icr.researchteam | Medicine (RMH Smith Cunningham) | en_US |
dc.contributor.icrauthor | Cunningham, David | |
dc.contributor.icrauthor | Chau, Ian | |
dc.contributor.icrauthor | Starling, Naureen | |